Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia

Igor Aluloski; Mile Tanturovski; Rubens Jovanovic; Slavica Kostadinova-Kunovska; Gordana Petrusevska; Igor Stojkovski; Bojana Petreska

doi:10.3889/oamjms.2017.215

Authors

Igor Aluloski University Clinic for Obstetrics and Gynecology, Skopje
Mile Tanturovski University Clinic for Obstetrics and Gynecology, Skopje
Rubens Jovanovic Institute of Patology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Slavica Kostadinova-Kunovska Institute of Patology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Gordana Petrusevska Institute of Patology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Igor Stojkovski University Clinic for Oncology and Radiotherapy, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje,
Bojana Petreska University Clinic for Oncology and Radiotherapy, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje,

DOI:

https://doi.org/10.3889/oamjms.2017.215

Keywords:

Ovarian cancer, High grade, Survival, Surgical cytoreduction

Abstract

AIM: The primary objective of the study was to evaluate the overall survival of women with advanced stage (Stage IIIA-IV) high-grade serous ovarian cancer in Macedonia

MATERIALS AND METHODS: The study was a cross-sectional medical record review of patients diagnosed with advanced stage HGSC. Patients were deemed eligible for inclusion if they were diagnosed with an advanced stage (Stage IIIA-IV) HGSC of the ovary, fallopian tube or peritoneum between 2009 and 2015.Â The data were analyzed in a descriptive fashion and summary statistics were provided, as appropriate. Survival was calculated using the Kaplan-Meier method.

RESULTS: A total of 81 eligible patients were identified and included in the study. The average overall survival in the studied cohort was 46.59 months (95%CI = 39.11-54.06). Patients that were optimally debulked and patients that had a platinum-free interval larger than 12 months had significantly longer survival in the current series (p < 0.001).

CONCLUSION: the average overall survival of advanced stage HGSC patients in the studied series was 46.59 months (95%CI = 39.11-54.06). Patients aged 65 years or younger tended to live approximately ten months longer than patients older than 65 years, but this difference was not statistically significant. There was no difference in HGSC survival in the groups of patients with grade 2 and grade 3 disease. However, optimal surgical debulking and platinum sensitivity were associated with significantly better overall survival.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719â€“25. https://doi.org/10.1038/nrc3144 PMid:21941283 PMCid:PMC3380637

Incidence and Mortality Worldwide: IARC Cancerbase number 11. Lyon, France: International Agency for Research on Cancer 2013. Available from: http://globocan.iarc.fr. Accessed April 2017.

National Cancer Institute. SEER (Surveillance, Epidemiology and End Results Program). SEER Cancer Fact Sheets: Cancer of the Ovary. Available from: http://seer.cancer.gov/statfacts/html/ovary.html. Accessed April 2017.

du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIGOCCC 2004). Ann Oncol. 2005;16(Suppl 8):7â€“12. https://doi.org/10.1093/annonc/mdi961 PMid:16239238

Cannistra SA. Cancer of the Ovary. New Engl J Med. 2004;351: 2519â€“29. https://doi.org/10.1056/NEJMra041842 PMid:15590954

Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130:107â€“14. https://doi.org/10.1016/j.ygyno.2013.03.026 PMid:23558050

Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Coebergh JW. Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res. 2005;124:89â€“107. https://doi.org/10.1007/0-387-23962-6_5 PMid:15839192

Gulbech Ording A, Garne JP, Witt NystrÃ¶m PM, FrÃ¸slev T, Toft SÃ¸rensen H, Lash TL. comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis â€“ a Danish nationwide matched cohort study. PLoS One. 2013;8(10):e76013. https://doi.org/10.1371/journal.pone.0076013 PMid:24130755 PMCid:PMC3794020

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26â€“35. https://doi.org/10.1002/path.2091 PMid:17117391

Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267â€“82. https://doi.org/10.1097/PAP.0b013e3181b4fffa PMid:19700937 PMCid:PMC2745605

Bowtell DD, Bohm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668â€“79. https://doi.org/10.1038/nrc4019 PMid:26493647 PMCid:PMC4892184

Hainsworth JD, Grosh WW, Burnett LS, Jones HW 3rd, Wolff SN, Greco FA. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med. 1988;108(2):165-70. https://doi.org/10.7326/0003-4819-108-2-165 PMid:3124679

Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer. 1991;27(11):1367-72. https://doi.org/10.1016/0277-5379(91)90011-2

Winter WE 3rd, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621-7. https://doi.org/10.1200/JCO.2006.10.2517 PMid:17704411

Markman M, Lewis JL Jr, Saigo P et al. Impact of age on survival of patients with ovarian cancer. Gynecol Oncol. 1993;49(2):236-9. https://doi.org/10.1006/gyno.1993.1113 PMid:8504993

Rabban JT, Bell DA. Current issues in the pathology of ovarian cancer. J Reprod Med. 2005;50(6):467-74. PMid:16050571

Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19(1):7-15. https://doi.org/10.1097/00004347-200001000-00003 PMid:10638449

Singer G, Kurman RJ, Chang H-W, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223â€“28. https://doi.org/10.1016/S0002-9440(10)62549-7

Vang R, Shih Ie M, Salani R, et al. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol. 2008;32:1667â€“74. https://doi.org/10.1097/PAS.0b013e31816fd555 PMid:18769340

Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25(20):2873-83. https://doi.org/10.1200/JCO.2007.11.0932 PMid:17617518

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(8):CD007565. https://doi.org/10.1002/14651858.CD007565.pub2

Dao F, Schlappe BA, Tseng J et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016;141(2):260-3. https://doi.org/10.1016/j.ygyno.2016.03.010 PMid:26968641 PMCid:PMC4844793